Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Amicus Spins Out Rare Disease Gene Therapy Pipeline, Raises $200m

Sep 29 2021

• By Joseph Haas

Empty dirt road which splits in two, concept for life choices or decisions — Amicus will split out its gene therapy R&D into Caritas

Related Content

Amicus Pompe Disease Combo’s Approvability In Question As Key Trial Misses Mark

Feb 12 2021

Tech Transfer Roundup: Amicus Adds Gene Therapy Technology In UPenn Partnership

Oct 17 2018

Tech Transfer Roundup: OncoSec Will Investigate CAR-T In Breast Cancer With Dana-Farber

Jul 03 2019

Finance Watch: Two SPAC Deals, Two IPOs Take Four Biopharmas Public

Apr 17 2021

Cerevel Goes Public In SPAC Merger To Fund Neuroscience Programs

Jul 30 2020

Amicus Makes Its Gene Therapy Move, Focusing On CNS Lysosomal Storage Disorders

Sep 20 2018

Amicus' Oral Fabry Drug Priced To Compete Against Traditional ERT

Aug 13 2018

Amicus To See If Its Fabry Drug Galafold Can Benefit From Mis-Diagnosed MS

Jan 30 2019

Related Companies

Amicus Therapeutics, Inc.

Celenex

University of Pennsylvania

Sanofi

Immatics N.V.

Cerevel Therapeutics Holdings, Inc.

Nautilus Biotechnology Inc.

Additional Topics

Business Strategies Deals Gene Therapy Financing Rare Diseases Research & Development Commercial BioPharmaceutical

More from Strategy

More from Business

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.